Treatments targeting the immune checkpoints IDO, CTLA-4, and PD-L1 reduced the number of tumor-infiltrating Tregs cells and improved mouse survival in a glioblast mouse model in previous studies, and combination targeted immunosuppressive therapy has high potential clinical value in high-grade malignant glioma37. Here, IDO1 is linked to neoplasm.